Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: JAKAFI

« Back to Dashboard
Jakafi is a drug marketed by Incyte Corp and is included in one NDA. It is available from one supplier. There are five patents protecting this drug.

The generic ingredient in JAKAFI is ruxolitinib phosphate. One supplier is listed for this compound. Additional details are available on the ruxolitinib phosphate profile page.

Summary for Tradename: JAKAFI

Suppliers: see list1

Pharmacology for Tradename: JAKAFI

Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors

Clinical Trials for: JAKAFI

Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Status: Recruiting Condition: Leukemia

Study of Ruxolitinib Plus Decitabine in Patients With Acute Myeloid Leukemia (AML)
Status: Recruiting Condition: Leukemia; Myeloproliferative Diseases

Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)
Status: Recruiting Condition: Myeloproliferative Diseases

Administration of Jakafi (Ruxolitinib) for Symptom Control of Patients With Chronic Lymphocytic Leukemia (CLL): Phase II
Status: Recruiting Condition: Leukemia

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Status: Recruiting Condition: Leukemia

Phase l/II Study of Ruxolitinib for Acute Leukemia
Status: Active, not recruiting Condition: Leukemia

Study of Ruxolitinib in Colorectal Cancer Patients
Status: Recruiting Condition: Metastatic Colorectal Cancer

Ruxolitinib Prior to Transplant in Patients With Myelofibrosis
Status: Recruiting Condition: Primary Myelofibrosis; Post Polycythemia Vera Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis

A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)
Status: Completed Condition: Primary Myelofibrosis

Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
Status: Recruiting Condition: Metastatic Breast Cancer; Breast Carcinoma; HER-2 Positive Breast Cancer

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Incyte Corp
ruxolitinib phosphate
TABLET;ORAL202192-004Nov 16, 2011RXNo<disabled><disabled>
Incyte Corp
ruxolitinib phosphate
TABLET;ORAL202192-005Nov 16, 2011RXYes8,822,481<disabled><disabled>
Incyte Corp
ruxolitinib phosphate
TABLET;ORAL202192-001Nov 16, 2011RXNo<disabled><disabled>
Incyte Corp
ruxolitinib phosphate
TABLET;ORAL202192-002Nov 16, 2011RXNo8,822,481<disabled><disabled>
Incyte Corp
ruxolitinib phosphate
TABLET;ORAL202192-003Nov 16, 2011RXNo7,598,257<disabled>YY<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn